CL2020002663A1 - Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos - Google Patents

Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos

Info

Publication number
CL2020002663A1
CL2020002663A1 CL2020002663A CL2020002663A CL2020002663A1 CL 2020002663 A1 CL2020002663 A1 CL 2020002663A1 CL 2020002663 A CL2020002663 A CL 2020002663A CL 2020002663 A CL2020002663 A CL 2020002663A CL 2020002663 A1 CL2020002663 A1 CL 2020002663A1
Authority
CL
Chile
Prior art keywords
preparation methods
positive allosteric
allosteric modulator
modulator compounds
gabaa positive
Prior art date
Application number
CL2020002663A
Other languages
English (en)
Inventor
Matthew Toczko
Jed Hubbs
Original Assignee
Neurocycle Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocycle Therapeutics Inc filed Critical Neurocycle Therapeutics Inc
Publication of CL2020002663A1 publication Critical patent/CL2020002663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En el presente documento se describen polimorfos que comprenden 2’,6-difluoro-5’-[3-(1-hidroxi-1-metiletil)-imidazo[1,2-b][1,2,4] triazin-7-il]bifenil-2-carbonitrilo (TPA023B) o sales del mismo. En un aspecto del presente documento se describe una sal polimórfica cristalina o cocristal de TPA023B con ácido fosfórico. En el presente documento también se describen métodos de preparación y uso de los mismos.
CL2020002663A 2018-04-18 2020-10-15 Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos CL2020002663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862659226P 2018-04-18 2018-04-18

Publications (1)

Publication Number Publication Date
CL2020002663A1 true CL2020002663A1 (es) 2021-06-11

Family

ID=68239798

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002663A CL2020002663A1 (es) 2018-04-18 2020-10-15 Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos

Country Status (14)

Country Link
US (2) US11542263B2 (es)
EP (1) EP3781566A4 (es)
JP (2) JP7449272B2 (es)
KR (1) KR20210011921A (es)
CN (1) CN112384513A (es)
AU (1) AU2019255282B2 (es)
BR (1) BR112020021104A2 (es)
CA (1) CA3096890A1 (es)
CL (1) CL2020002663A1 (es)
IL (1) IL278067A (es)
MX (2) MX2020010878A (es)
SG (1) SG11202010220QA (es)
TW (1) TW202012402A (es)
WO (1) WO2019204446A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3096890A1 (en) * 2018-04-18 2019-10-24 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
CN113840610A (zh) * 2019-03-18 2021-12-24 纽罗塞克医疗公司 Gabaａ受体调节剂用于治疗疼痛的用途
CN114981266A (zh) * 2019-10-22 2022-08-30 纽罗塞克医疗公司 Gabaa正向变构调节剂化合物、其制备方法和用途
MX2022004945A (es) * 2019-10-23 2022-08-04 Neurocycle Therapeutics Inc Tratamiento de afecciones epilépticas con moduladores del receptor gabaa.
US20210401849A1 (en) * 2020-06-30 2021-12-30 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
WO2024076999A2 (en) * 2022-10-04 2024-04-11 Engrail Therapeutics, Inc. Gabaa receptor modulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
EP1343788B1 (en) * 2000-11-10 2005-11-23 MERCK SHARP & DOHME LTD. Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
CA2724742C (en) 2008-05-21 2016-07-19 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US20110082147A1 (en) * 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
EP3407886A1 (en) * 2016-01-27 2018-12-05 Universität Zürich Use of gabaa receptor modulators for treatment of itch
CA3096890A1 (en) * 2018-04-18 2019-10-24 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Also Published As

Publication number Publication date
WO2019204446A1 (en) 2019-10-24
JP2024063136A (ja) 2024-05-10
US11542263B2 (en) 2023-01-03
AU2019255282B2 (en) 2024-08-08
EP3781566A1 (en) 2021-02-24
CA3096890A1 (en) 2019-10-24
KR20210011921A (ko) 2021-02-02
US20210040103A1 (en) 2021-02-11
MX2020010878A (es) 2021-01-29
AU2019255282A1 (en) 2020-11-05
MX2024004400A (es) 2024-04-29
JP2021522330A (ja) 2021-08-30
TW202012402A (zh) 2020-04-01
IL278067A (en) 2020-11-30
EP3781566A4 (en) 2022-06-22
JP7449272B2 (ja) 2024-03-13
BR112020021104A2 (pt) 2021-02-23
US20230139418A1 (en) 2023-05-04
SG11202010220QA (en) 2020-11-27
CN112384513A (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
CL2020002663A1 (es) Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos
CL2020002848A1 (es) Sales de un inhibidor de fgfr.
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CL2020002839A1 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas.
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
NI201800058A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CL2020002530A1 (es) Ciano tienotriazolpirazinas y usos de las mismas.(divisional de solicitud 621-2018)
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CO2018014339A2 (es) Formas sólidas cristalinas de un inhibidor de bet
ECSP20029142A (es) Ligandos de psma para la formación de imágenes y endorradioterapia
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2017000223A1 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
DOP2019000228A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
CL2022000980A1 (es) Compuestos moduladores alostéricos positivos de gabaa, métodos de preparación y usos de los mismos
MX2020003832A (es) Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.
BR112021018357A2 (pt) Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma